In this multicentre, double-blind, parallel-group study, 120 out-patients with mild to moderate primary hypertension were randomised, after a 4-week single-blind placebo run-in period, to a combination tablet of felodipine-metoprolol 5/50 mg (Logimax ® , Mobloc ® , Astra) once daily or enalapril 10 mg once daily. If blood pressure (BP) remained suboptimally controlled after 4 weeks (supine diastolic BP Ͼ90 mm Hg 24-h post dose), the dose was doubled for a further 4 weeks. After 8 weeks felodipine-metoprolol reduced supine BP significantly more than enalapril (19.7/12.0 mm Hg and 11.1/7.2 mm Hg, respectively). The mean differences in change in BP between treatments were 8.6/4.8 mm Hg in favour of felodipine-metoprolol (P ‫؍‬ 0.001/P Ͻ0.001). A statistically significant difference to the advantage of felodipine-metoprolol was also seen in standing BP. Even though the dose was increased in a larger proportion of
Introduction
In their 1993 Guidelines, the World Health Organisation/International Society of Hypertension (WHO/ISH) recommended five drug classes (diuretics, ␤-blockers, ACE inhibitors, calcium antagonists and ␣ 1 -blockers) for consideration in the first-line treatment of mild hypertension. 1 Despite the availability of these drug classes, however, current management of mild hypertension often fails to meet long-term treatment goals. 2, 3 Consequently, there is a need to provide patients with a more effective antihypertensive medication which will enable more patients to reach target blood pressure (BP) while maintaining good tolerability.
The WHO/ISH Committee recognised the inherent advantage of combination therapy using low doses Correspondence: Dr Ove K Andersson, Associate Professor, Hypertension Clinic, Department of Internal Medicine, Gö teborg School of Medicine, Sahlgrenska Universitetssjukhuset, S-413 45 Gö teborg, Sweden Received 2 July 1998; revised and accepted 27 August 1998 patients in the enalapril group (61%) than in the felodipine-metoprolol group (40%), fewer enalapril-treated patients achieved adequate BP control (41% vs 63% on felodipine-metoprolol, P Ͻ0.05). Both treatments were well tolerated. Three patients treated with felodipinemetoprolol and four with enalapril discontinued treatment due to adverse events. A similar number of patients reported adverse events in each treatment group. In conclusion, a combination tablet of felodipinemetoprolol 5/50-10/100 mg once daily reduced BP more effectively than enalapril 10-20 mg once daily 24 h post dose. The result was expected, but a more important observation was that both treatments were tolerated to a similar degree. Obviously, a considerable BP reduction may be well tolerated, as was the main purpose to demonstrate in this study.
of drugs acting by complementary antihypertensive mechanisms. 1 The Committee further noted that it would be appropriate to combine two medications in a single tablet or capsule for reasons of convenience, cost and increased patient compliance. 1 These recommendations are consistent with the recent JNC VI recommendations. 4 One such combination is available as an extended-release (ER) tablet containing the vascular specific calcium antagonist felodipine and the ␤ 1 -selective adrenergic antagonist metoprolol (Logimax ® , Mobloc ® , Astra). 5, 6 As a highly vascular selective dihydropyridine calcium antagonist, felodipine lowers BP by reducing total peripheral vascular resistance without affecting cardiac contractility or conduction. 7 Metoprolol acts by the complementary mechanism of ␤-blockade, reducing heart rate and cardiac output. 8 A combination of felodipinemetoprolol in an ER formulation releases two compounds at a controlled rate, thereby maintaining smooth plasma concentration profiles throughout the dose interval is maintained. The ER tablet has been shown to provide reliable 24-h BP control, 5, 6, 9 56 reducing the risk of side effects related to peak plasma concentrations.
Several studies have shown that the felodipinemetoprolol combination is more effective in reducing BP 24 h post dose and controls BP in a greater proportion of patients than the respective monotherapies, without compromising tolerability. [10] [11] [12] Efficacy and tolerability are also maintained during long-term treatment. 13 Enalapril is a widely used ACE inhibitor that effectively reduces BP when administered once daily in patients with mild to moderate hypertension. 14 The aim of the present study was to test whether a combination tablet of felodipine and metoprolol administered once daily in out-patients with mild to moderate primary hypertension would provide better BP control, without compromising tolerability, than enalapril administered once daily.
Materials and methods
The study was performed in accordance with the Declaration of Helsinki and approved by the local Ethics Committees. After giving written informed consent, out-patients were enrolled at 12 Swedish centres (5-15 patients per centre). The basic design was a multicentre, randomised, double-blind, parallel group trial preceded by a single-blind placebo run-in period to wash out any previous antihypertensive medication and establish baseline.
Out-patients of either gender aged 20-70 years with primary hypertension were eligible to enter. Supine diastolic BP (DBP) (phase V) had to be 95-115 mm Hg following a 4-week single-blind run-in placebo period after withdrawal of any previous antihypertensive medication. Exclusion criteria comprised: secondary hypertension; supine systolic BP (SBP) Ͼ200 mm Hg; significant renal, hepatic or cardiac disease; known intolerance or contraindication to use of calcium antagonists, ␤-blockers or ACE inhibitors; severe concomitant disease which might interfere with patient assessment (eg, malignancy); conditions associated with poor compliance; child-bearing potential without reliable contraception and concomitant treatment with other investigational drugs.
In total 120 Caucasian patients (73 women and 47 men; mean age 55 years) with mild to moderate primary hypertension were randomised to felodipinemetoprolol 5/50 mg once daily (n = 59) or enalapril 10 mg (n = 61) once daily for 4 weeks. If supine DBP remained Ͼ90 mm Hg at this time, the dosage was increased to felodipine-metoprolol 10/100 mg once daily or enalapril 20 mg once daily, which was continued for a further 4 weeks. The total treatment duration was 8 weeks. A double-dummy technique was used to maintain blindness. Study medication was taken once daily in the morning, and the tablets had to be swallowed whole with a glass of water. Compliance was determined by returned tablet counts. No antihypertensive medications except the study drugs were permitted during the trial and, as far as possible, other concomitant medication was kept stable throughout the trial.
All clinical measurements were done at 24 ± 2 hours after the last intake of the study drug. Supine and standing BPs were measured to the nearest 2 mm Hg in the same arm at each visit using a standard mercury sphygmomanometer. Heart rate was measured by pulse palpation for 30 sec immediately after BP recording in each position. BP and heart rate were recorded after 5 min supine rest and 1 min in the standing position. All measurements were made in duplicate with at least 1 min between measurements, and the average was used. The full medical history of the patients was recorded at initial recruitment prior to the placebo run-in period. A medical examination (including body weight and ECG) was also performed at the start (baseline, week 0) and end (week 8) of treatment with study medication. Blood and urine samples were collected at week −2 and week 8 (and at week 0 if abnormal values were found at week −2) for routine laboratory tests (clinical chemistry and haematology).
All unfavourable events, whether or not considered causally related to the study medication, were recorded as adverse events. These were graded as mild, moderate or severe. A causal relationship to study medication was graded by the investigator only for adverse events considered as serious. Adverse events were those reported spontaneously by the patient, in response to non-specific questioning, or any clinically relevant changes in laboratory variables, ECG, or other clinical tests (including change in concomitant medication or deterioration in concurrent illness). Adverse events were recorded at visits at weeks −2, 0, 4 and 8.
Statistical evaluation was performed according to the all-patients-treated approach. The treatment effect was evaluated by comparing differences in the main efficacy variable supine DBP from baseline to 4 and 8 weeks by using a two-way analysis of variance with treatment, centre and interaction of treatment and centre as factors. Since all analyses include measurements taken after randomisation, only patients who had at least one value after baseline were included in the analysis. Secondary variables, ie, SBP and heart rate, as well as standing DBP, SBP and heart rate, were analysed in the same way. The proportion of patients with adequate control of the BP (ie, supine DBP р90 mm Hg) and the proportion of responders (ie, supine DBP р90 mm Hg and/or a reduction у10 mm Hg) were analysed with the Mantel-Haenszel test stratified for centre. A rounded P-value of Ͻ0.05 was considered as statistically significant. Results are expressed as mean values ± standard deviation.
Results
The baseline demographic and clinical characteristics of the groups at randomisation were well balanced (Table 1) . A total of 114 patients completed the study.
All BPs, ie, supine and standing, systolic and diastolic, were reduced after 4 and 8 weeks both with felodipine-metoprolol and enalapril ( Figure 1 , Table  2 ). However, felodipine-metoprolol reduced supine and standing systolic and diastolic BP significantly (Figure 1 ). The mean for the difference in change in systolic and diastolic BP between treatments was 8.5/4.8 mm Hg in favour of felodipinemetoprolol (P Ͻ0.01, Table 3 ). Similarly, the reduction in standing BP was significantly more pronounced with felodipine-metoprolol than with enalapril after both 4 and 8 weeks. The mean difference in change between treatments was 8.9/5.3 mm Hg after 4 weeks (P Ͻ0.01) and 7.1/3.5 mm Hg after 8 weeks (P = 0.015; P Ͻ0.01, Table 4 ). No patient in any group developed orthostatic hypotension. There was no statistically significant difference in supine or standing heart rate in the enalapril group at weeks 4 or 8 vs baseline. Heart rate was, however, reduced in the felodipine-metoprolol group: supine by 4.9 and 7.2 beats/min after 4 and 8 weeks treatment, respectively and standing by 4.4 and 6.1 beats/min after 4 and 8 weeks treatment, respectively.
Even though a larger proportion of patients (61%) received a dose increase in the enalapril-treated group than in the felodipine-metoprolol group (40%), fewer enalapril-treated patients (41% vs 63% at 8 weeks, P Ͻ0.05) achieved adequate BP control. Similarly, there was a larger proportion of responders after 8 weeks with felodipine-metoprolol (79%) than with enalapril (50%, P Ͻ0.01).
The changes in laboratory values were relatively minor and in no case were they considered clinically significant.
A similar number of patients reported adverse events in both groups. Table 5 shows the number of patients by the most common new-onset adverse events (reported by at least three patients) during active drug treatment compared with placebo runin. As expected, the most common adverse events were headache, peripheral oedema and a feeling of warmth/flushing in the felodipine-metoprolol group and headache, cough and fatigue in the enalapril 
group. Three patients on felodipine-metoprolol and four patients on enalapril discontinued study treatment due to adverse events.
Discussion
This trial revealed that felodipine-metoprolol has greater antihypertensive efficacy than the established and well tolerated antihypertensive agent enalapril. Fewer patients in the felodipine-metoprolol group required a dose increase at week 4, which indicates that the patients in this group reached target DBP more quickly. The percentage of patients achieving an adequate DBP response was 79% after 8 weeks' treatment in the felodipine-metoprolol group, which is similar to the success rate of around 85% achieved after 12 weeks of treatment with felodipine-metoprolol in other trials. [10] [11] [12] This high efficacy can be attributed to the complementary primary actions of felodipine and metoprolol, which have the advantage of limiting the counter-regulatory mechanisms that otherwise tend to counteract the antihypertensive effect. 15 Many studies have now indicated the complementary action achieved by combining low doses of felodipine and metoprolol in the short-to medium-term treatment of primary hypertension 11, 12, 16, 17 as well as isolated systolic hypertension. 18 Furthermore, this high degree of efficacy is maintained during long-term treatment of primary hypertension for up to 1 year without the development of tolerance. 13 Monotherapy with drugs from the five available major antihypertensive drug classes (diuretics, ␤-blockers, ACE inhibitors, calcium antagonists and ␣ 1 -blockers) does not usually achieve normotension in more than 50% of patients. 15 In the present study, enalapril, 10-20 mg once daily, achieved normotension at 24 h post dose (supine DBP р 90 mm Hg) in only 41% of patients, while this was significantly higher (63%) with the felodipine-metoprolol combination tablet, 5/50-10/100 mg once daily. The current study confirms that the once-daily administration of the combined felodipine-metoprolol tablet is effective in achieving target BP.
This result was expected, but a more important observation was that both treatments were tolerated to a similar degree. It is interesting to note that the felodipine-metoprolol combination did not cause more adverse effects than enalapril. Both enalapril and the felodipine-metoprolol combination tablet proved to be well tolerated in the study reported here. Adverse effects were generally mild and transient, the most common adverse events being vasodilatory with felodipine-metoprolol and typical ACE inhibitor-induced side effects, such as cough, with enalapril. There was the expected heart rate reduction in the group receiving felodipine-metoprolol, related to ␤-blockade by metoprolol. No unexpected findings were recorded in either group, nor were any unexpected haematological or biochemical changes seen in routine laboratory tests.
A number of studies have indicated that the outcome of antihypertensive treatment in clinical practice is often disappointing. For example, in a recent general practice study in five European countries involving over 10 000 hypertensive patients, Ménard 3 reported that only 37% reached the target DBP set by their physician. Also, only 21% of hypertensive patients treated in the US reached a BP below a threshold level of 140/90 mm Hg. 2 It is well established that hypertensive patients have an increased risk of cardiovascular morbidity and mortality, 19, 20 and that this is reduced by antihypertensive therapy. [21] [22] [23] [24] [25] However, it is important to note that the greatest benefits of antihypertensive therapy are obtained in those who have the largest reduction of BP, 26 or, to put it another way, there is higher cardiovascular morbidity and mortality in those who do not achieve target BP reduction. 27, 28 In the light of these data, the additional BP reduction produced by the felodipine-metoprolol combination tablet may well have important clinical implications.
In conclusion, it was demonstrated that the combination tablet of felodipine-metoprolol 5/50-10/100 mg once daily reduces BP more effectively than enalapril 10-20 mg once daily 24 h post dose in patients with mild to moderate primary hypertension. Both treatments were well tolerated, as indicated by the small number of adverse event reports and withdrawals from therapy. Thus, the efficacy/ tolerability balance of combination treatment such as felodipine-metoprolol may be equal to or better than that obtained with monotherapy such as enalapril.
